The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ARCELLX INC COMMON STOCK 03940C100   551,777,926 6,720,803 SH   SOLE   6,720,803 0 0
ARCUS BIOSCIENCES INC COM 03969F109   427,376,736 31,424,760 SH   SOLE   31,424,760 0 0
ASSEMBLY BIOSCIENCES INC COM NEW 045396207   115,338,010 4,505,391 SH   SOLE   4,505,391 0 0
GALAPAGOS NV SPON ADR 36315X101   578,747,003 16,707,477 SH   DFND 1 16,707,477 0 0
TANGO THERAPEUTICS INC COM 87583X109   40,777,321 4,854,443 SH   SOLE   4,854,443 0 0
KYVERNA THERAPEUTICS INC COM 501976104   24,756,714 4,126,119 SH   SOLE   4,126,119 0 0
XILIO THERAPEUTICS INC COM 98422T100   7,673,164 9,105,451 SH   SOLE   9,105,451 0 0
LEAP THERAPEUTICS INC COM NEW 52187K200   2,414,893 5,319,148 SH   SOLE   5,319,148 0 0
MERUS N V COM N5749R100   42,605,417 452,527 SH   SOLE   452,527 0 0